# A Single Centre Study to Evaluate the Safety and Immunogenicity of the Human Papillomavirus Vaccine (GSK-580299) in Chinese Females

> **NCT00549900** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 30 (actual)

## Conditions studied

- Infections, Papillomavirus

## Interventions

- **BIOLOGICAL:** GSK580299 (Cervarix™ , HPV -16/18 L1 VLP AS04 vaccine)

## Key facts

- **NCT ID:** NCT00549900
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-12-02
- **Primary completion:** 2008-07-12
- **Final completion:** 2008-07-12
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2018-07-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00549900

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00549900, "A Single Centre Study to Evaluate the Safety and Immunogenicity of the Human Papillomavirus Vaccine (GSK-580299) in Chinese Females". Retrieved via AI Analytics 2026-09-25 from https://api.ai-analytics.org/clinical/NCT00549900. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*